Evans syndrome: clinical perspectives, biological insights and treatment modalities

José Carlos Jaime-Pérez
Patrizia Elva Aguilar-Calderón
Lorena Salazar-Cavazos
David Gómez-Almaguer

Department of Hematology, Internal Medicine Division, Dr José E González University Hospital, School of Medicine of the Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México

Abstract: Evans syndrome (ES) is a rare and chronic autoimmune disease characterized by autoimmune hemolytic anemia and immune thrombocytopenic purpura with a positive direct anti-human globulin test. It is classified as primary and secondary, with the frequency in patients with autoimmune hemolytic anemia being 37%–73%. It predominates in children, mainly due to primary immunodeficiencies or autoimmune lymphoproliferative syndrome. ES during pregnancy is associated with high fetal morbidity, including severe hemolysis and intracranial bleeding with neurological sequelae and death. The clinical presentation can include fatigue, pallor, jaundice and mucosal bleeding, with remissions and exacerbations during the person’s lifetime, and acute manifestations as catastrophic bleeding and massive hemolysis. Recent molecular theories explaining the physiopathology of ES include deficiencies of CTLA-4, LRBA, TPP2 and a decreased CD4/CD8 ratio. As in other autoimmune cytopenias, there is no established evidence-based treatment and steroids are the first-line therapy, with intravenous immunoglobulin administered as a life-saving resource in cases of severe immune thrombocytopenic purpura manifestations. Second-line treatment for refractory ES includes rituximab, mofetil mycophenolate, cyclosporine, vincristine, azathioprine, sirolimus and thrombopoietin receptor agonists. In cases unresponsive to immunosuppressive agents, hematopoietic stem cell transplantation has been successful, although it is necessary to consider its potential serious adverse effects. In conclusion, ES is a disease with a heterogeneous course that remains challenging to patients and physicians, with prospective clinical trials needed to explore potential targeted therapy to achieve an improved long-term response or even a cure.

Keywords: Evans syndrome, autoimmune cytopenias, low-dose rituximab, IVIG, systemic lupus erythematosus, HSCT, sirolimus, mofetil mycophenolate, HSCT

Introduction

Evans syndrome (ES) is an uncommon autoimmune disease that was defined by Robert Evans in 1951 when he studied the relationship between autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP). He described the first diagnosis criteria of ES, including the presence of anemia, reticulocytosis, increased blood bilirubin and fecal urobilinogen, no family history of hemolytic diseases, evidence of antibodies against erythrocytes at 37°C, hemolysis of transfused erythrocytes, the presence of purpura, prolonged bleeding time, bone marrow aspiration with normal or increased number of megakaryocytes and the absence of exogenous toxic agents or a baseline disease. Evans divided five groups of patients and demonstrated the presence of a serum agglutinating factor in patients with ITP1 based on previously reported
observations in guinea pigs and rabbits. Some authors modified the definition of Evans as a destruction of at least two hematological blood lineages, as observed in patients with neutropenia, hemolytic anemia and thrombocytopenia. Importantly, AIHA is a complex syndrome with a warm, cold, mixed and biphasic thermal behavior of antibodies, but only warm ones characterize ES.

The typical course of ES is characterized by an heterogeneous chronic disease with clinical variability at onset, spontaneous remissions and exacerbations. Its worldwide frequency is unknown; however, research of ES in AIHA is available in some cohorts that report an incidence of about 37%–73% in this setting. A higher rate in female gender has been reported in 60%–70% of ES patients.

### Diagnosis

First, an exhaustive clinical history must be taken to determine the risk factors for developing ES, such as infections, malignancies, autoimmune diseases, recent vaccinations, drugs or a family history of immune disorders, complemented with a thorough physical examination focused on signs of anemia or thrombocytopenia. It is important to mention that primary ES is a diagnosis of exclusion and secondary ES must be searched for to determine a baseline disease because treatment and responses considerably differ between primary and secondary ES.

Characterization of laboratory features requires a complete blood count and direct examination of peripheral blood; anemia, thrombocytopenia, reticulocytosis, poikilocytosis, mainly due to the presence of spherocytes, increased indirect bilirubin and lactate dehydrogenase and a positive direct anti-human globulin test (DAT) test confirming ongoing immune hemolysis are to be expected. The main laboratory characteristics are summarized in Figure 1.

Additional studies can include the detection of antibodies against platelets (PA-IgG), documented in 35% of individu-

---

**Figure 1** Diagnostic approach for Evans syndrome.

**Abbreviations:** aCL, antiphospholipid; ALPS, autoimmune lymphoproliferative syndrome; ANA, antinuclear antibodies; anti-CCP, anti-cyclic citrullinated peptide; anti-LC1, anti-liver cytosol antibody; anti-MCV, anti-mutated citrullinated vimentin; anti-Sm, anti-Smith antibody; APS, antiphospholipid syndrome; CVID, common variable immunodeficiency; LA, lupus anticoagulant; LKM-1, liver kidney microsomal type 1 antibodies; PA-IgG, platelet-associated IgG; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SMA, smooth muscle antibody; TSH, thyroid stimulating immunoglobulin; VEGF, vascular endothelial growth factor.
als, mostly type anti-IIb-IIIa. Anti-granulocyte antibodies can be detected in some patients, but a lack of these antibodies does not exclude neutrophil involvement. Other antibodies must be considered to identify main autoimmune diseases associated with ES. The diagnostic work up is shown in Figure 1.

**Clinical features**

Clinical features are associated with anemia and thrombocytopenia including pallor, weakness, fatigue, jaundice, petechiae, ecchymosis, gingivorrhagia and epistaxis. Due to the prolonged immunosuppressive therapy and/or the associated underlying immune deficit, there is a risk of 66.6% of patients developing respiratory tract infections.

**Differential diagnosis of ES**

There are some diseases with similar characteristics to ES. Main differential diagnoses are as follows: hemolytic uremic syndrome, characterized by microangiopathic hemolytic anemia, thrombocytopenia, leukocytosis, negative DAT test, clinically manifested as diarrhea, vomiting, fever, pallor, acute renal failure in children predominantly secondary to infections with *Escherichia coli*, *Shigella dysenteriae* or *Streptococcus pneumoniae*; thrombotic thrombocytopenic purpura, a disease associated with a functional deficit of ADAMTS 13 presenting as microangiopathic hemolytic anemia, thrombocytopenia, fever and neurological or kidney impairment; Kasabach–Merritt syndrome, a rare disease predominant in early infancy with a high mortality rate of about 30% characterized by microangiopathic hemolytic anemia, thrombocytopenia, low fibrinogen levels, increment of D-dimer and giant hemangioma, and paroxysmal nocturnal hemoglobinuria, a chronic life-threatening disease with hemolytic anemia, pancytopenia and thrombosis of vital organs, mainly in adults. These pathologies must be excluded because treatment is considerably different in each.

**Pathophysiology**

Several authors have proposed different disease pathways, summarized by the presence of immune dysregulation with antibodies against erythrocytes, platelets and/or granulocytes and decreased CD4:CD8 ratio. Mechanisms currently proposed for explaining ES are shown in Table 1; the pathophysiology of ES remains unknown. In the following section, immunologic alterations observed in this syndrome are exposed in the larger context of autoimmunity and other relevant data are theoretically extrapolated to the disease.

**Deficiency of CTLA-4 (CD152) and LRBA**

CTLA-4 or CD152 is an inhibitory transmembrane receptor at the surface of regulatory T-cells that bind with a high affinity to CD80/CD86 molecules in antigen-presenting cells with subsequent endocytosis and downregulation contributing to immune homeostasis. This deficiency has been related to ES; on the other hand, LRBA is an intracellular protein that binds to CTLA-4 cytoplasmic fraction in regulatory T-cells following its endocytosis, avoiding its degradation. CTLA-4 deficiency as a cause of alteration in T-cell homeostasis has been documented in an animal model. Recently, a gene mutation in LRBA and CTLA-4 proteins has been related to patients with ES, also, this immune dysregulation has been found in recurrent severe opportunistic infections in humans and fatal lymphoproliferative disease in mice.

**Deficit of TPP2**

A recent clinical trial revealed that tripeptidyl peptidase 2 (TPP2) is a molecule with an important role in aging, immu-

---

**Table 1** Principal mechanisms proposed to explain the pathogenesis of Evans syndrome

| Studies                | Design            | Population | Patients | Mechanism                                                                 |
|------------------------|-------------------|------------|----------|---------------------------------------------------------------------------|
| Besnard et al, 2018    | Retrospective     | Children   | 18       | CTLA-4, LRBA, KRAS, STAT3 gain-of-function mutations are associated with ES secondary to a loss of T-cell homeostasis. |
| Stepensky et al, 2015  | Clinical trial    | Children   | 2        | TPP2 is an essential molecule for cell survival under stress; deficiency is associated with higher levels of autoantibodies, ABCs, perforins and MHC I, with a consequent immunosuppression; there is an increased risk for viral infections and development of autoimmunity. |
| Karakantza et al, 2000 | Short report      | Children   | 1        | Increased levels of Th1 cytokines, especially INF-γ, explains the presence of autoreactive B-cells against platelets and erythrocytes, confirmed by the lower levels of IFN-γ after splenectomy. |

**Abbreviations:** ABCs, age-associated B cells; ES, Evans syndrome; INF, interferon; MHC I, major histocompatibility complex I; CTLA-4, cytotoxic T-lymphocyte antigen 4; LRBA, lipopolysaccharide responsive beige-like anchor protein; TPP2, tripeptidyl peptidase 2.
nosesenescence, autoimmunity and tumorigenesis. Its deficiency is associated with ES.21 Serological analysis shows that the deficit of TPP2 is related to the presence of anti-nucleolar, anti-cyttoplasmic, anti-nuclear antibodies and an increased level of age-associated B cells (ABCs), CD11c+ , with a higher expression of major complex histocompatibility I molecules. This may indicate the presence of antigens on their surface, explaining the association between ABCs and autoimmune diseases.21 ABCs are usually present in the elderly and have been demonstrated in patients with autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis or scleroderma and systemic sclerosis.22 Further studies are needed to clearly understand the specific role of these cells in ES and autoimmune disease pathophysiology.

**Decreased CD4/CD8 ratio**

Abnormalities of immune regulation have been demonstrated in ES patients with a decreased level of T helper and increased T cytotoxic cells with a low CD4:CD8 ratio compared with healthy controls. Excessive production of T cytotoxic lymphocytes or a diminished activity of T helper cells could avoid the production of immunoglobulins (Ig) M and G, as observed in common variable immunodeficiency (CVID) patients.17 It has been recently shown in vitro that after CD8+ T-cell activation, there are increased levels of interferon gamma with a subsequent stimulation of autoreactive B-cells against erythrocytes and platelets.21 It could be that this increased activity of T-CD8+ cells favors deficiency of CTLA-4, which regulates inflammatory cytokine production.20 These mechanisms could plausibly cause a disruption of T-cell homeostasis with an elevated concentration of interferon gamma and subsequent activation of B-cells against erythrocytes and platelets.

**Classification**

Classification of ES includes primary/idiopathic, with this being an exclusion diagnosis with no underlying condition, and secondary in the presence of a baseline disease. It has been demonstrated that secondary disease responds better than primary ES.24 Multiple miscellaneous causes of secondary ES have been documented.25-52

**Secondary ES**

**Autoimmune lymphoproliferative syndrome**

Previously named Canale–Smith syndrome,53 autoimmune lymphoproliferative syndrome (ALPS) is a disorder characterized by a Fas gene mutation with an alteration in T-cell apoptotic pathways causing lymphoproliferation manifested as hepatomegaly, splenomegaly, lymphadenopathies, an increased risk of Hodgkin lymphoma and immune cytopenia, mainly AIHA and ITP, with the presence of antibodies against erythrocytes and platelets,54 features similar to those observed in autoimmune multilineage cytopenia.50 Diagnostic criteria for ALPS were established in 1999 by the National Institutes of Health and require two necessary criteria, such as the presence of chronic lymphoproliferation, increased levels of double-negative T-cells and one primary accessory criterion with a deficit of apoptosis in vitro or genetic mutation in FAS, FASL and/or CASP 10.55 Some authors suggest ruling out this diagnosis in all pediatric patients with AIHA and ES.54 Others consider ALPS as a cause of secondary ES, as reported in a center with a higher frequency of concomitant ALPS and ES in 47%–50% of patients, confirmed by the presence of elevated double-negative T-cells.56,57 It is important to diagnose ALPS before starting treatment, since it is not recommended to administer rituximab to these patients except in specific severe unresponsive cases because of an association with developing hypogammaglobulinemia, which has been reported. CVID has also been considered as a cause of secondary ES.38,40 A recent study documented the increased expression of Fas in patients with ES and CVID.41 Interestingly, an association between ALPS and ES has been documented only in children.56,57

**Systemic lupus erythematosus**

Several studies have demonstrated the relationship between SLE and ES,9,10,58 prevalence of secondary ES in SLE has been reported in 1.7%–2.7% of cases.24,59 Hemorrhagic manifestations are frequently observed in this group, including petechiae, ecchymosis, epistaxis, gingivorrhagia, gastrointestinal bleeding and hematuria.5,59 Spontaneous splenic rupture as an initial manifestation of ES has been documented,60 confirming the heterogeneous course of the disease. Steroids are the suggested first line of therapy.61 In refractory cases, rituximab at standard doses has proven effective with a reduction in PA-IgG, DAT strength,62 decreased antinuclear antibodies (ANA) titer, and anti-CD19, -CD21, -B3, -TNF-α 1–6 months after treatment.62,63 Autologous hematopoietic stem cell transplant in a refractory case with SLE, antiphospholipid syndrome and ES led to clinical remission, negative ANA and DAT tests, plausibly explained by a graft vs immunity effect.64 Interestingly, secondary ES has a longer remission than the primary disease.24

**Autoimmune hepatitis**

The relationship between ES and autoimmune hepatitis has been reported by few centers, with main clinical features
including pallor, fatigue and splenomegaly.\(^6\) Diagnosis for autoimmune hepatitis and ES is confirmed by the presence of elevated hepatic enzymes, ANA, anti-smooth muscle antibody, DAT, PA-IgG and a confirmatory biopsy with rosette formation.\(^6\) Initial treatment with prednisolone and rituximab is recommended to prevent refractoriness as observed with some immunosuppressants such as azathioprine, mycophenolate mofetil (MMF) and intravenous immunoglobulin (IVIG). Improvement in cytopenias and normalization of hepatic enzymes have been observed, mainly with rituximab, in a year of follow-up.\(^6,67-69\)

**Chronic lymphocytic leukemia**

CLL is a worldwide common cause of hematologic cancer in the elderly.\(^70\) It is frequently associated with autoimmune cytopenias.\(^70,71\) The frequency of ES in CLL is 2.9%.\(^72\) A diagnosis of secondary ES in CLL requires the presence of AIHA and ITP at onset or within 1 month of the baseline disease. Determination of genetic mutations is necessary to establish prognosis in CLL. A 13q14 deletion is the most common chromosomal alteration and is associated with a good prognosis;\(^73\) however, poor prognostic factors are predominant in patients with ES and CLL, such as a 17p13 deletion, presence of ZAP-70 and a mutation of TP53,\(^72\) explaining the lower survival rate in these cases, compared to patients with only CLL.

**ES during childhood**

The incidence of ES in children is unknown due to a lack of published studies, with the few available consisting of case reports or retrospective cohorts.\(^6,12,59,74-76\) From the largest cohorts of autoimmune cytopenias, it can be concluded that ES is more frequent during childhood; in a study, 11 (4.1%) of 179 children had ES\(^v\) vs 6 (0.78%) of 766 adults.\(^77\) It is important to note that autoimmune cytopenias in children are frequently associated with primary immunodeficiencies and in this group, they should always be ruled out.\(^78\)

A referral center of autoimmune cytopenias in France has been operating since 2004, and children with ITP, AIHA and ES have been prospectively evaluated in the OBS’CERÉVANCE cohort.\(^7,79\) A report from this prospective cohort included 156 children from 26 different centers; median age was 5.4 years (0.2–17.2) with a male:female ratio of 1.44. Sixty-nine percent of children required more than one line of treatment, including rituximab, azathioprine, splenectomy, cyclosporine and MMF.\(^80\)

A large multicenter retrospective study in 21 hospitals included 42 children with a median age of 7.7 years. These patients received 1–12 modalities of treatment, mostly steroids plus IVIG, whereas others underwent splenectomy and/or received cyclosporine, vincristine, danazol, azathioprine, cyclophosphamide and plasmapheresis, with no optimal response. Twenty-four (58%) patients had complications – 12 hemorrhagic and 12 suffered severe infections, mainly sepsis, pneumonia, meningitis, abscess and osteomyelitis.\(^3\)

In pediatric ES cases lack of response or relapse can be severe, even after splenectomy or the use of multiple immunosuppressive agents. In addition, no large clinical trials assessing outcomes for different treatment strategies and long-term responses in children have been published.

**ES during pregnancy**

ES during pregnancy is not frequent and usually the diagnosis is established previously; main differential diagnoses in this circumstance are HELLP syndrome, thrombotic thrombocytopenic purpura and uremic hemolytic syndrome. There is a passive immune transfer of maternal IgG antibodies via placenta to the fetal circulation, which explains the transient thrombocytopenia or hemolytic anemia previously reported in newborns or fetus of women with autoimmune cytopenia.\(^81\) In general, pregnant women with ES have a good outcome if appropriate treatment is administered opportunistically; however, there is an increased risk of developing abruptio placenta and postpartum hemorrhage. Fetuses usually have a bad prognosis associated with high-risk complications occurring such as severe hemolytic anemia or hemorrhages secondary to significant thrombocytopenia, mainly intracranial bleeding with intra-extrauterine death or neurological impairments. Hematological therapy is challenging because of drugs’ teratogenic effects; treatment of choice is steroids plus IVIG. Its action mechanisms include a decreased level of antibodies crossing the placenta\(^82\) and of maternal IgG antibodies by downregulation, with a reduction of these in fetal circulation.\(^83\) Last treatment options are azathioprine or splenectomy, exclusively in refractory third trimester cases.\(^84\)

**Treatment**

There are no clinical trials available for ES treatment and indications for starting therapy have not been established by evidence-based studies. Few retrospective reports and small cohorts have documented responses which are summarized in Table 2.

It is reasonable to treat patients with clinically significant decreased platelet and hemoglobin levels; nevertheless, as observed in ITP, the decision to start therapy in non-symptomatic patients varies in each case depending on physician experience.\(^11\)
The main objective consists of achieving a long-term complete response. There is no therapeutic regimen established. Steroids with and without IVIG are recommended as front-line therapy.\(^{11,12,85}\) Red blood cell/platelet transfusion is indicated only in severe symptomatic patients due to the risk of exacerbations.\(^{11}\)

### First-line treatments

**Steroids**

It is postulated that steroids inhibit the ability of macrophages for clearing platelets and erythrocytes.\(^{86}\) Prednisolone or prednisone at 1–2 mg/kg/day\(^{11,12}\) must be administrated in all cases, and in patients with severe clinical manifestations, an initial dose of 4–6 mg/kg/day within the first 72 hours is recommended. The initial response rate documented for patients who receive steroids at 1–2 mg/kg/day is about 82%–83%.\(^{8}\) A regimen including a prednisolone megadose of 30 mg/kg/day for 3 days, then 20 mg/kg/day for 4 days, followed by progressive tapering to 10, 5, 2, 1 mg/kg/week has been administered and most patients have shown complete response.\(^{6,11,75}\) Three weeks after starting treatment patients need a re-evaluation; if complete response is achieved, slow tapering within 6 months is necessary to avoid adverse effects. In patients with a partial response, the initial

### Table 2 Second-line therapeutic options for patients with Evans syndrome

| Drug                | Dose                              | Route of administration | Results                                      |
|---------------------|-----------------------------------|-------------------------|----------------------------------------------|
| Rituximab           | N/A                               | N/A                     | CR: 5; PR: 4; NR: 2                          |
|                     | 375 mg/m²/week/4 doses\(^{89}\)   | N/A                     | Remission: 1/1                               |
|                     | 375 mg/m²/week/3–4 doses\(^{74}\) | N/A                     | Remission: 13                                |
|                     | 375 mg/m²/week/4 doses\(^{90}\)   | N/A                     | Good response                               |
|                     | 375 mg/m²/week/4 doses\(^{61}\)   | IV                      | Remission: 1/1                               |
|                     | 375 mg/m²/week/4 doses\(^{102}\)  | IV                      | Good response: 1/1                           |
|                     | 375 mg/m²/week/4 doses\(^{11}\)   | IV                      | NR: 1                                        |
|                     | 375 mg/m²/day/8 doses\(^{103}\)   | N/A                     | NR: 1                                        |
|                     | 375 mg/m²/week/3 doses\(^{96}\)   | IV                      | Response: 5/5                                |
|                     | 375 mg/m²/week/4 doses\(^{18}\)   | IV                      | Remission: 1/1                               |
|                     | 375 mg/m²/week\(^{97}\)          | IV                      | Patient 1: NR to AIHA, but CR for ITP;       |
|                     |                                  |                         | Patient 2: NR; Patient 3: CR for AIHA,      |
|                     |                                  |                         | NR for ITP; Patient 4: NR to AIHA           |
|                     | 375 mg/m²/3 weeks/5 doses\(^{105}\) | IV                      | Good response: 1/1                           |
|                     | 375 mg/m²/week\(^{106}\)         | IV                      | Remission: 1/1                               |
|                     | 375 mg/m²/week/6 weeks\(^{13}\)  | IV                      | Remission: 2/2                               |
|                     | 375 mg/m²/week/4 weeks\(^{14}\)  | IV                      | Response: 1/1                                |
| Alemtuzumab         | 10 mg/day/10 days\(^{14}\)       | IV                      | Response: 2; transient response: 1           |
| Mycophenolate mofetil | 650 mg/m²/b.d.\(^{108}\)      | N/A                     | Response: 14                                 |
|                     | 50 mg/kg/day\(^{111}\)           | N/A                     | Complete remission: 1/1                      |
|                     | 50 mg/kg/day\(^{110}\)           | N/A                     | Sustained remission: 1/1                     |
|                     | 500 mg/day, then 1–3 g/day\(^{158}\)  | N/A                     | Response: 10, one with ES                    |
|                     | 500 mg/day/b.d., then 1 g/day/b.d.\(^{107}\) | N/A                     | Response: 4                                  |
| Cyclosporine        | N/A\(^{11}\)                    | N/A                     | Relapse                                      |
|                     | 6 mg/kg/day\(^{15}\)            | N/A                     | Response: 1/1                                |
|                     | N/A\(^{13}\)                    | N/A                     | CR: 16/18                                    |
|                     | 10 mg/kg/day/8 months\(^{116}\)  | N/A                     | Remission: 1/1                               |
|                     | 5 mg/kg/day/b.d. for 6 days, then 3 mg/kg/day\(^{118}\) | N/A | PR: 1/1                                     |
|                     | 5–6 mg/kg/day divided b.d.\(^{120}\) | N/A                     | Oral Response: 5                             |
|                     | 10 mg/kg/day, alternative days\(^{117}\)  | N/A | Response                                     |
| Cyclophosphamide    | 1,000 mg\(^{137}\)              | IV                      | CR: 6/8                                      |
|                     | 50 mg/kg/day/4 days\(^{15}\)     | N/A                     | Remission: 1; NR: 1                           |
|                     | 500 mg/m²/4 weeks\(^{30}\)      | N/A                     | PR: 1/1                                      |

**Abbreviations:** AIHA, autoimmune hemolytic anemia; b.d., twice daily; CR, complete response; ES, Evans syndrome; ITP, immune thrombocytopenic purpura; IV, intravenous; N/A, not available; NR, no response; PR, partial response.
Intravenous immunoglobulin
Concentrated IgG from human plasma donors acts by blocking the Fcγ receptor on the macrophages,89 which remains a controversial therapy. In some centers, it is recommended as a first-line treatment together with steroids, and in others as a complementary drug in severe thrombocytopenic patients. A Canadian guideline recommends IVIG only in patients with predominance of ITP symptoms; in cases where AIHA symptoms are more conspicuous, other treatments are preferred.90 IVIG was first indicated in 1950 for primary immune deficiencies, but it is currently an important therapy for autoimmune and hematologic diseases such as acquired hemophilia, acquired hypogammaglobulinemia, acquired von Willebrand disease, aplastic anemia, AIHA, autoimmune neutropenia and ES.90 This is an important life-saving resource in uncontrolled patients;11 the most common dose administered is 0.4 g/kg/day for 4 days and 5 g/kg in the case of predominance of AIHA.91 Before using this therapeutic modality, it is important to consider its expense which is about 4,000 Canadian dollars per dose.90 A high risk of presenting adverse effects including fever, headache, fatigue, nausea, palpitations and myalgias occurs in 20%–30% of patients.92,93 Severe complications have been documented, consisting mainly of acute kidney injury, arterial and venous thromboembolic events, aseptic meningitis, hemolytic anemia and infections.94

Second-line treatment
Rituximab
Rituximab is a chimeric anti-CD20 targeted drug that has been increasingly used as the second-line treatment in steroid-refractory or relapsing ES. It has an immunosuppressive effect with B-cell depletion in peripheral blood after one infusion.95

A pediatric multicentric prospective study analyzed the efficacy of rituximab at 375 mg/m² in 15 patients with refractory AIHA. All patients previously received two or more courses of immunosuppressive agents (steroids, azathioprine, IVIG, cyclosporine and azathioprine) and 5/15 had ES; of these 5 patients, 3 responded with an increment in platelet levels from 27 to 140×10⁹/L, 2 months after starting rituximab.96 Another multicenter cohort retrospectively evaluated 68 adults with ES; eleven received rituximab at the standard dose with an initial response of 82% after a mean of 12 months, and two of the eleven patients relapsed.9

A retrospective research investigated the use of rituximab at the standard dose plus prednisoone in 17 refractory children with ES. An overall response of 76% was achieved; the main side effects during rituximab administration were vomiting, facial edema and rash, and at 1–2 weeks after infusion, transient neutropenia and pneumonia developed in one patient.74 This suggested that adding rituximab to steroids can be effective in refractory cases, mainly as a second-line treatment, and emphasized the fact that repeated doses are efficient in relapsing patients. The effects of rituximab in 14 patients with immune cytopenias including 4 ES cases were reported. No patient had a concomitant response in both AIHA and ITP, suggesting that rituximab can be effective only in some patients with refractory ES.97 There are ten case reports of single patients treated with rituximab, eight adults and two children; nine of these ten patients achieved remission.34,98–106 These studies suggest that rituximab is a good option in refractory patients, and that repeated courses are necessary to achieve long-term responses. We have previously reported the outcome of six patients with ES treated at our institution, four women and two men with an age range of 10–42 years. Three received steroids as the first-line treatment and low doses of rituximab, 100 mg/week/4 weeks, as the second-line treatment with a good clinical response; after second relapse, however, two patients required splenectomy.10

Mycophenolate mofetil
The 2-morpholinoethyl ester of mycophenolic acid is a selective, competitive immunosuppressant prodrug that reduces lymphocyte proliferation by inhibition of inosine monophosphate dehydrogenase.107 Some authors have shown its efficacy in autoimmune cytopenias.12,107 A recent retrospective multicenter study evaluated the use of MMF in 40 and 16 children with ITP and ES, respectively. Most patients previously received one to three lines of treatment; 13/16 cases achieved a complete response and only 1 patient had nausea as a secondary effect.108 The excellent response in that study encourages further clinical trials as it proved that MMF is safe and effective for ES, confirming its administration as a second–third line therapy.11,109 Effectiveness of MMF has been associated with a sustained complete remission as observed in two children; the first case was refractory to steroids and IVIG10 and the second to steroids, IVIG, rituximab,
 vincristine and cyclophosphamide. Both patients received MMF at 50 mg/kg/day, while the second patient also received cyclosporine A. The use of MMF has been related to a higher risk of developing lymphoma. Nevertheless, in a prospective study of 200 patients, main adverse effects were epigastric pain and headache, with no manifestations suggestive of lymphoma. A dose of 600 mg/m² of MMF twice a day followed by an evaluation 3 months after the initial treatment is recommended because of the risk of relapse and scarce information on the long-term adverse effects. These results suggest that MMF can be a useful and safe second-line treatment for ES patients refractory to steroids or IVIG.

Cyclosporine
Cyclosporine has been used in small series of patients with ES since 1994. It is an immunosuppressive drug whose mechanism of action is that it inhibits the activation of T-cells. A total of 28 patients have been treated with this modality in different studies. Most were refractory to steroids, IVIG or another immunosuppressant. A response was observed in 26/28 refractory patients; thus, cyclosporine can achieve an excellent response in these circumstances. Nevertheless, it is important to carefully select patients considered for this drug in cases with no response to less-toxic drugs. If administered, continuous monitoring of serum concentrations of cyclosporine is mandatory due to the severe adverse effects associated with its administration, including malignancy and nephrotoxicity, which have been observed after administration of low doses of cyclosporine (6 mg/kg/day) after 20 years of treatment.

Splenectomy
Splenectomy was the only option in refractory relapsing patients before the introduction of rituximab, being classically considered as a second-line treatment in patients with autoimmune cytopenias, achieving a response of 60%–75% in AIHA and ITP, while in ES, the responses are documented to be considerably heterogeneous, between 0% and 66%. Recently, splenectomy has been replaced by rituximab due to the risks of the surgical procedure. It is important to mention that in children <6 years of age, it is not a recommended option because of a higher risk of septicemia/meningitis with S. pneumoniae, Neisseria meningitidis or Haemophilus influenzae with both classic and laparoscopic techniques. Also, splenectomy is contraindicated in patients with ALPS due to an elevated risk of sepsis and recurrent multilineage cytopenias.

Reported complications after splenectomy in patients with hematologic diseases include bleeding, infections and thromboembolic events. Recently, a case report with fatal pulmonary embolism as a consequence of splenectomy in a patient with ES was published. Laparoscopic splenectomy is an option that could avoid some secondary adverse effects, as observed in five patients with ES who underwent laparoscopic splenectomy. Two cases achieved normalization of the platelet count at a mean of 18 months and did not require additional treatment. One patient had a good initial response, but required additional medical treatment after 18 months, and two cases did not respond.

Third-line treatments
Cyclophosphamide
Cyclophosphamide is a powerful alkylating agent with antimitotic and immunomodulatory effects, is used in cancer and autoimmune diseases. It is able to suppress an ongoing immune response. Although few centers have analyzed the use of cyclophosphamide in ES, a slow but progressive response has been described. In a report, 48 patients with autoimmune cytopenias associated with CLL were evaluated. Eight had ES and were treated concomitantly with rituximab, dexamethasone and cyclophosphamide, achieving an overall response of 75%. The duration of response of CLL patients was shorter in cases of ES compared to AIHA or pure red cell aplasia. In another center, cyclophosphamide was administered in a refractory child at a dose of 500 mg/m² intravenously (IV), achieving a good response with improvement of hemoglobin and platelet levels. It is known that the use of this drug is associated with a higher frequency of adverse effects, including infections and secondary malignancies. Current results suggest that cyclophosphamide can induce remission in ES patients and it could be administered as a third–fourth-line option in refractory cases.

Alemtuzumab
A humanized monoclonal antibody against CD52 has recently been tested for AIHA and ITP and was found to show a good response. This antibody exerts its action through depleting lymphocytes; recently, we studied this therapeutic option in refractory ITP and AIHA at 10 mg on days 1 and 3 administered subcutaneously in combination with subcutaneous rituximab at 100 mg/week/month, and the response was 100%. A prospective cohort of 21 patients with autoimmune cytopenias received alemtuzumab IV at 20 mg/day for 10 days; 3 patients had ES, 2 responded, whereas the third had a transient response. The first patient achieved...
a response within 1 week, but relapsed at 3 months and received cyclosporine and a second course of alemtuzumab. The second patient responded 3 days after administration of treatment, but relapsed at 3 months and received a second course of alemtuzumab; however, this patient died due to a cerebral hemorrhage. The last patient achieved a transient response and died because of lung cancer.\textsuperscript{134}

**Thrombopoietin-receptor agonists**

Second generation of thrombopoietin receptor agonists, romiplostim and eltrombopag, had a potential effect stimulating thrombopoiesis as observed in ITP,\textsuperscript{135} and recently in ES, as documented in a patient refractory to steroids, splenectomy, IVIG and rituximab who received eltrombopag, romiplostim plus steroids with a duration of remission of 40 days at the last follow-up, suggesting that the combination of drugs is effective in decreasing platelet destruction and increasing the proliferation and maturation of megakaryocytic cells, as observed with steroids and thrombopoietin receptor agonists, respectively; this could be a highly effective double-targeted therapeutic approach.\textsuperscript{136} Another center reported a patient refractory to rituximab who received romiplostim at 1–2 µg/kg/week/4 doses and after splenectomy was performed, with a remission duration of 153 days since the first romiplostim administration.\textsuperscript{137}

**Hematopoietic stem cell transplantation**

Scarc reports have documented the use of stem cell transplantation in ES. The main benefit of allogeneic HSCT is that it currently constitutes the only curative treatment option for ES by resetting the immune system;\textsuperscript{138} thus, this therapy could be a valuable alternative for patients with multiple relapses, with severe complications affecting their quality of life and/or if a lack of response to immunosuppressive drugs exists.

**Allogeneic HSCT**

In 1997 the first case report of a child with ES treated with ten different therapeutic immunosuppressive lines without a good response was published. The patient suffered severe bleeding (intracranial, gastrointestinal) and considerable neurological impairment. Due to his unresponsive disease, an allogeneic cord blood transplant was performed with a conditioning regimen of cyclophosphamide, 200 mg/kg plus anti-thymocyte globulin at 90 mg/kg. Three months after transplant, antibodies against erythrocytes and platelets were negative with 100% chimerization. He maintained complete remission for the 30 months of follow-up.\textsuperscript{140}

**Autologous HSCT**

A prospective non-randomized study analyzed the use of cyclophosphamide at 50 mg/kg/day with autologous depleted peripheral blood stem cells for ITP in five cases with ES. They received 6–14 lines of treatment prior to transplant. Three achieved complete response and two did not respond. All cases presented bacteremia and one died after developing multiple myeloma.\textsuperscript{141}

In another case, a female adult received an autologous HSCT. She suffered SLE plus antiphospholipid syndrome and suddenly developed florid ES. The conditioning regimen was cyclophosphamide at 50 mg/kg/day, anti-T lymphocyte globulin 10 mg/kg/day and 6-methylprednisone 1 g/day. The patient achieved a good response with normal blood counts.\textsuperscript{64}

A child with refractory ES received a double autologous stem cell transplant and achieved a short-term response. On relapse, unrelated umbilical cord blood transplantation was performed with a conditioning regimen of busulfan, thiotepa, etoposide and antithymocyte globulin. After cord blood transplant, the patient achieved a good response.\textsuperscript{142}

The largest retrospective study of autoimmune cytopenias treated with HSCT included 36 patients, wherein 7 had ES. Five received an allogeneic HSCT and one achieved remission, two died and two were not evaluated. This suggests that auto-HSCT can be an alternative in severe autoimmune cytopenias.\textsuperscript{143}

Graft vs host disease has an important effect in eliminating auto-antibodies against platelets and erythrocytes, with a higher rate and prolonged remission in secondary cases of ES. The high risk of morbidity has restricted the use of HSCT for treating ES and other autoimmune diseases. Thus, results suggest that it is important to start therapy with medical treatments. If there is no response or the patient has a chronically relapsing course and if a human leukocyte antigen-identical sibling donor is available, allogeneic HSCT is preferred. In older patients with significant comorbidities who lack a human leukocyte antigen-identical donor, autologous HSCT could be performed.\textsuperscript{144}

**ES secondary to solid organ or HSCT**

Solid organ and bone marrow transplantation has been associated to the development of ES in some centers.\textsuperscript{145–151} The
main mechanism behind this association is still unknown; immunosuppression secondary to chemotherapy of maintenance regimen could be implicated to an immune dysregulation of T-cells. In 19 infants with genetic diseases, a mismatched cord blood transplantation was performed with a conditioning regimen of busulfan, cyclophosphamide and antithymocyte globulin; 10 cases developed chronic graft versus host disease with autoimmune cytopenias and 3 had ES. A child with recurrent Hodgkin lymphoma underwent an autologous stem cell transplantation, after 15 months the patient developed ES refractory to steroids and IVIG; cyclosporine A was effective in this case. A female patient with recurrent Hodgkin disease treated with an autologous bone marrow transplant with a conditioning regimen of cyclophosphamide, etoposide and carmustine developed ES. A patient with non-Hodgkin lymphoma with multiple relapses received a peripheral blood stem cell transplant with a conditioning regimen of etoposide, carboplatin and cyclophosphamide; 49 days after transplantation the patient developed ES, non-Hodgkin lymphoma relapsed and died. Also, development of refractory ES in a patient with multiple myeloma treated with an autologous stem cell transplantation has been documented.

Additional potential supporting interventions

Anecdotic reports suggest that immunological benefits can be gained in patients with autoimmune diseases including SLE and rheumatoid arthritis from simple measures, including oral honey drink and Nigella sativa oil or powder as nutritional support measures. It is reported that wet cupping therapy (Al-Hijamah) can clear patients’ blood from autoantibodies, inflammatory mediators and immunological noxious substances.

Perspectives in ES

New treatment approaches for patients suffering from ES should lead to long-lasting remissions, less-severe relapses and an increased opportunity for cure. These scenarios will be possible as knowledge of the molecular landscape in this intriguing disease deepens, thus allowing the design of sophisticated biological therapy and/or improved HSCT strategies for severe cases, particularly in children.

A Phase II active clinical trial (Identifier: NCT00392951) recently evaluated sirolimus at 3 mg/m² and then at 2.5 mg/m² depending on its serum levels in refractory autoimmune cytopenias including ES. A total of 30 patients were evaluated, including 8 with ES. There were three complete responses, three partial responses and two patients with no response. Main objectives were to document toxicities of sirolimus, including mucositis, elevation of triglycerides and cholesterol and to assess the efficacy of this approach in patients with refractory ES.

Conclusion

ES is a rare disease with a heterogeneous course characterized by multiple relapses during lifetime, despite multimodal treatment. A combination of genetic and epigenetic factors appears to be involved in its pathogenesis, and the knowledge of its precise etiology will help to design specific targeted therapies with less-severe adverse effects, significantly improving patients quality of life. Results with currently available therapeutic modalities are unsatisfactory and the disease runs a chronic relapsing course, eventually complicated by catastrophic clinical events that can lead to death. Prospective studies and clinical trials derived from knowledge on its pathophysiology are needed to improve the long-term response and even cure individuals suffering ES.

Acknowledgment

We thank Sergio Lozano-Rodriguez, MD, for his critical review of the manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Evans R, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired haemolytic anaemia: evidence for a common etiology. *AMA Arch Intern Med*. 1951;87(1):48–65.
2. Bedson SP. Blood-Platelet anti-serum, its specificity and role in the experimental production of purpura. *J Pathol Bacteriol*. 1922;24:94–104.
3. Mathew P, Chen G, Wang W. Evans syndrome results of a national survey. *J Pediatr Hematol Oncol*. 1997;19(5):433–437.
4. Savasan S, Warrier I, Ravindranath Y. The spectrum of Evans’ syndrome. *Arch Dis Child*. 1997;77(3):245–248.
5. Dhingra KK, Jain D, Mandal S, Khurana N, Singh T, Gupta N. Evans syndrome: a study of six cases with review of literature. *Hematology*. 2008;13(6):356–360.
6. Pai CH, Willimas J, Wang W. Evans syndrome in childhood. *J Pediatr*. 1980;97(3):754–758.
7. Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. *Haematologica*. 2011;96(5):655–663.
8. Besnard C, Levy E, Aladjidi N, et al. Pediatric-onset Evans syndrome: heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. *Clin Immunol*. 2018;188:52–57.
9. Michel M, Chaval V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. *Blood*. 2009;114(15):3167–3172.
10. Jaime-Pérez JC, Guerra-Leal LN, López-Razo ON, Méndez-Ramírez N, Gómez-Almaguer D. Experience with Evans syndrome in an academic referral center. *Rev Bras Hematol Hemoter*. 2015;37(4):230–235.
11. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006;132(2):125–137.
12. Miano M. How I manage Evans syndrome and AIHA cases in children. Br J Haematol. 2016;172(4):524–534.
13. Corrigan JJ Jr, Boineau FG. Hemolytic-uremic syndrome. Pediatr Rev. 2001;22(11):365–369.
14. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–2846.
15. Kim JA, Choi YB, Yi ES, et al. Excellent outcome of medical treatment for Kasabach–Merritt syndrome: a single-center experience. Blood Res. 2016;51(4):256–260.
16. Maguiness S, Guenther L. Kasabach–Merritt syndrome. J Cutan Med Surg. 2002;6(4):335–339.
17. Wang W, Herrod H, Pui CH, Presbury G, Wilimas J. Immunoregulatory
18. Schmidt RE, Grimbacher B, Witte T. Autoimmunity and primary immunodeficiency: two sides of the same coin? Nat Rev Rheumatol. 2018;14(1):7–18.
19. Lo B, Fritz JM, Su HC, et al. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood. 2016;128(8):1037–1042.
20. Friedline RH, Brown DS, Nguyen H, et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med. 2009;206(2):421–434.
21. Stepensky P, Rensing-Ehl A, Gather R, et al. Early-onset Evans syndrome, immunodeficiency, and premature immunosenescence associated with tripeptidyl-peptidase II deficiency. Blood. 2015;125(5):753–761.
22. Rubtsov AV, Rubtsova K, Fischer A, et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD1 Ics B-cell population is important for the development of autoimmunity. Blood. 2011;118(5):1305–1315.
23. Karakantza M, Mouzaki A, Theodoropoulou M, Bussel JB, Maniatis A. Th1 and Th2 cytokines in a patient with Evans’ syndrome and profound lymphopenia. Br J Haematol. 2000;110(4):968–970.
24. Costallat GL, Appenzeller S, Costallat LT. Evans syndrome and systemic lupus erythematosus: clinical presentation and outcome. Joint Bone Spine. 2012;79(4):362–364.
25. Lambotte O, Gelu-Simeon M, Maigne G, et al. Pegylated interferon alpha-2a-associated life-threatening Evans’ syndrome in a patient with chronic hepatitis C. J Infect. 2005;51(3):e113–e115.
26. Shivalingaiah SK, Arpana J, Jain MK, Varghese VK. Hyperhomocysteinemia and Evans syndrome with uncal herniation for emergency splenectomy. Anesth Essays Res. 2015;9(1):118–120.
27. Yokoyama S, Kasahara M, Fukuda A, et al. Evans syndrome after successful living-donor liver transplantation for neonatal giant cell hepatitis. Transplantation. 2007;84(6):798–799.
28. Sharma S, Dasgupta S, Suman SK, Kumar U, Chitkera S. Dissemi-
29. Radhakrishnan S, Sugiyama S, Anand K, Sharshar T. Evans syndrome in a patient with chronic hepatitis C and human immunodeficiency virus infection. J Rheumatol. 2004;31(10):2342–2344.
30. Traggiai E, Corthals K, Groenewoud F, et al. Immunology of the corticoids–danazol combination. Rev Rhum Mal Osteoartic. 1991;58(7):519–522 French.
31. Quinn JP, Gilligan OM, Horgan M. Evans’ syndrome complicating multicentric Castleman’s disease—dramatic response to rituximab. Eur J Haematol. 2004;73(5):384–385.
32. Dave P, Krishna K, Diwan AG. Evans’ syndrome revisited. J Assoc Physicians India. 2012;60:60–61.
33. Ikeda K, Maruyama Y, Yokoyama M, et al. Association of Graves’ disease with Evans’ syndrome in a patient with IgA nephropathy. Intern Med. 2001;40(10):1004–1010.
34. Yashiro M, Nagoshi H, Kasuga Y, et al. Evans’ syndrome associated with Graves’ disease. Intern Med. 1996;35(12):987–990.
35. García-Muñoz R, Anton J, Rodriguez-Otero P, et al. Common variable immunodeficiency and Evans syndrome complicated by autoimmune hemolyis due to anti-IgA auto-antibodies. Leuk Lymphoma. 2008;49(6):1220–1222.
36. Azizi G, Abolhasani H, Asgardoorn MH, et al. Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management. Expert Rev Clin Immunol. 2017;13(2):101–115.
37. Podjasec JK, Abraham RS. Autoimmune cytopenias in common variable immunodeficiency. Front Immunol. 2012;3:189.
38. Savaşan S, Warrier I, Buck S, Kaplan J, Ravindranath Y. Increased lymphocyte Fas expression and high incidence of common variable immunodeficiency disorder in childhood Evans’ syndrome. Clin Immunol. 2007;125(3):224–229.
39. Paaske H, Srensen CW, Astrup L. Evans’ syndrome in IgA deficiency. Episodic autoimmune haemolytic anaemia and thrombocytopenia during a 10 years observation period. Scand J Haematol. 1982;265–270.
40. Roca B, Ferrán G, Simón E, Cortés V. Lymphoid hyperplasia of the lung and Evans’ syndrome in IgA deficiency. Am J Med. 1999;106(1):121–122.
41. Bechir A, Haifa R, Nesrine BS, et al. Multiple myeloma associated with an Evans’s syndrome. Pan Afr Med J. 2016;25:127.
42. Yamamoto G, Hosoi M, Miyagawa T, et al. Evans syndrome with cytomegalovirus infection followed by emerging peripheral T-cell lymphoma. Am Hematol. 2012;91(1):123–124.
43. Shlamovitz GZ, Johar S. A case of Evans’ syndrome following influenza vaccine. J Emerg Med. 2013;44(2):e149–e151.
44. Martínez E, Domingo P. Evans’s syndrome triggered by recombiant hepatitis B vaccine. Clin Infect Dis. 1992;15(6):1051.
45. Hyun D, Kim D, Jung J, Sohn S, Lee J, Lee K. A case of Epstein–Barr virus infection presented as Evans syndrome. Blood Res. 1998;33(3):438–442.
46. Olgönenel B, Moonka D, Savaşan S. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol. 2006;81(4):302.
47. Kubota T, Daibata M, Kobayashi M, Taguchi H. [Malignant lymphoma of the lung associated with Evans’ syndrome: report of a case]. [Article in Japanese]. Nikken Kohyuki Gakkai Zasshi. 2002;40(12):965–969.
48. D’Ambrosio D, Tomaselli V, Gargiulo G, della-Morte D, Abete P. Evans syndrome presented with marginal zone lymphoma and duodenal neuroendocrine tumor in an elderly woman. Int J Gerontol. 2016;10(4):237–239.
49. Amid A, Leung E. Evans syndrome secondary to HIV infection. J Pediatr Hematol Oncol. 2013;35(6):490–491.
50. Canale VC, Smith CH. Chronic lymphadenopathy simulating malign-
51. Garrido Colino C. Avances en el conocimiento y manejo del síndrome linfoproliferativo autoinmune. An Pediatr (Barc). 2016;84(4):237–240.
52. Amid A, Leung E. Evans syndrome secondary to HIV infection. J Pediatr Hematol Oncol. 2013;35(6):490–491.
53. Canale VC, Smith CH. Chronic lymphadenopathy simulating malign-
54. Garrido Colino C. Avances en el conocimiento y manejo del síndrome linfoproliferativo autoinmune. An Pediatr (Barc). 2016;84(4):237–240.
55. Oliveira JB, Blessing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35–e40.
56. Seif AE, Mannos CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010;115(11):2142–2145.
57. Teachey DT, Mannos CS, Assom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lympho-
58. Perspect Biol Med. 2018;61(4):214–215.
59. Teachey DT, Mannos CS, Assom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lympho-
60. Dobbs DJ, Mannos CS, Teachey DT. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105(6):2443–2448.
58. Thakur N, Chandra J, Dhingra B, Singh V. Pediatrik lupus: varied haematological picture and presentation. Indian J Hematol Blood Transfus. 2015;31(1):68–70.

59. Lube GE, Ferriani MP, Campos LM, et al. Evans syndrome at childhood-onset systemic lupus erythematosus diagnosis: a large multicenter study. Pediatr Blood Cancer. 2016;63(7):1238–1243.

60. Tokgoz H, Caliskan U, Atas B, Ozbek O, Tavil B. Spontaneous rupture of the spleen in a patient with systemic lupus erythematosus initially presented as Evans syndrome. J Pediatr Hematol Oncol. 2014;36(1): c39–e41.

61. Mendonca S, Srivastava S, Kapoor R, Gupta D, Gupta P, Sharma ML. Evans syndrome and its link with systemic lupus erythematosus. Saudi J Kidney Dis Transpl. 2016;27(1):147–149.

62. Kittaka K, Dobashi H, Baba N, et al. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab. Scand J Rheumatol. 2008;37(5):390–393.

63. Tamimoto Y, Horiuchi T, Tsukamoto H, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans’ syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatism (Oxford). 2008;47(6):821–827.

64. Musso M, Porretto F, Crescimanno A, et al. Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus. 1998;7(7):492–494.

65. Ohkawara H, Furukawa M, Ikeda K, et al. Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report. Int J Hematol. 2017;106(5):718–724.

66. Tiniakos DG, Brain JG, Bury YA. Role of histopathology in autoimmune hematopoiesis. Dig Dis. 2015;33(2):53–64.

67. Korkmaz H, Bugdaci MS, Temel T, Dagli M, Karabagli P. Autoimmune hepatitis–primary biliary cirrhosis overlap syndrome concomitant with immune hemolytic anemia and immune thrombocytopenic purpura (Evans syndrome). Clin Res Hepatol Gastroenterol. 2013;37(2):e45–e50.

68. Jarasvaraparn C, Imran H, Siddiqui A, Wilson F, Gremse DA. Association of deleted cells both influence prognosis in chronic lymphocytic leukaemia: presentation, treatment, and outcome. Am J Pediatr Hematol Oncol. 2011;50(8):633–643.

69. Pasquet M, Aladjidi N, Guiton C, et al. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French Experience. Br J Haematol. 2014;164(2):266–271.

70. Aladjidi N, Fernandes H, Leblanc T, et al. Evans syndrome in children: long-term outcome in a prospective French national observational cohort. Front Pediatr. 2015;3:79.

71. Sankaran S, Robinson SE. Immune thrombocytopenia and pregnancy. Obstet Med. 2011;4(4):140–146.

72. Phupong V, Sareepapong W, Witoonpanich P. Evans syndrome and pregnancy: a case report. J.OBG. 2004;111(3):274–276.

73. Dal Bo M, Rossi FM, Rossi D, et al. 13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2011;50(8):633–643.

74. Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood. 2014;124(15):2337–2344.

75. Santeri N, Dagi T, Clohisy K, et al. Rituximab therapy in refractory autoimmune hemolytic anemia and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report. Int J Hematol. 2017;106(5):718–724.

76. Mantadakis E, Farmaki E. Natural history, pathogenesis, and treatment of Evans syndrome in children. J Pediatr Hematol Oncol. 2017;39(6):413–419.

77. Mizutani H, Furubayashi T, Imai Y, et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW × BXSB) F1. Blood. 1992;79(4):942–947.

78. Flores-Montes OA, Escober-Orduño MC, Lozano-Garcidueñas M, Valle-Leal JL. Síndrome de Evans en lactantes. Bol Med Hosp Infant Mex. 2017;74(2):141–146.

79. Feng C, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993;44(4):237–242.

80. Godbeau P, Bierling P. Treatment of idiopathic thrombocytopenic purpura in adults. Presse Med. 2008;37(9):1292–1298.

81. Sankaran S, Robinson SE. Immune thrombocytopenia and pregnancy. Obstet Med. 2011;4(4):140–146.

82. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for refractory Evans syndrome and other immune-mediated hematologic diseases. Transfus Med. 2007;21(2 Suppl 1):S9–S56.

83. Flores-Montes OA, Escober-Orduño MC, Lozano-Garcidueñas M, Valle-Leal JL. Síndrome de Evans en lactantes. Bol Med Hosp Infant Mex. 2017;74(2):141–146.

84. Varela-Moragas A, Varela-Perez Y, Rodriguez-Rodriguez D, et al. Safety of intravenous immunoglobulin therapy. J Crit Care. 2007;22(1):53–59.

85. Sankaran S, Robinson SE. Immune thrombocytopenia and pregnancy. Obstet Med. 2011;4(4):140–146.

86. Pasquet M, Aladjidi N, Guiton C, et al. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French Experience. Br J Haematol. 2014;164(2):266–271.

87. Aladjidi N, Fernandes H, Leblanc T, et al. Evans syndrome in children: long-term outcome in a prospective French national observational cohort. Front Pediatr. 2015;3:79.

88. Sankaran S, Robinson SE. Immune thrombocytopenia and pregnancy. Obstet Med. 2011;4(4):140–146.

89. Mantadakis E, Farmaki E. Natural history, pathogenesis, and treatment of Evans syndrome in children. J Pediatr Hematol Oncol. 2017;39(6):413–419.

90. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for refractory Evans syndrome and other immune-mediated hematologic diseases. Transfus Med. 2007;21(2 Suppl 1):S9–S56.

91. Sankaran S, Robinson SE. Immune thrombocytopenia and pregnancy. Obstet Med. 2011;4(4):140–146.
102. Knecht H, Baumberger M, Tobón A, Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology. 2004;63(4):730–732.

103. Urban C, Benesch M, Sovinz P, Schwingen W, Lackner H. Fatal Evans’ syndrome after matched unrelated donor transplantation for hyper-IgM syndrome. Eur J Haematol. 2004;72(6):444–447.

104. Galor A, O’Brien T. Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome. Int J Hematol. 2003;78(4):335–339.

105. Seipel G, Böhme A, Koschmieder S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolymphocytic transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol. 2001;80(3):170–173.

106. Abdel-Raheem MM, Potti A, Kobrinsky N. Severe Evans’ syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody. Ann Hematol. 2001;80(9):543–545.

107. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117(3):712–715.

108. Miano M, Ramenghi U, Russo G, et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian Association of Paediatric Haematology/Oncology. Br J Haematol. 2016;175(3):490–495.

109. Miano M, Scalzone M, Perri K, et al. Mycophenolate mofetil and sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune cytopenias: a single centre experience. Br J Haematol. 2015;171(2):247–253.

110. Guirat-Dhouib N, Mellouli F, Kouki R, Bejaoui M. Successful treatment of mycophenolate mofetil in a child with refractory Evans syndrome. J Pediatr Hematol Oncol. 2010;32(6):e244.

111. Farruggia P, Macaluso A, Troipa S, et al. Effectiveness of cyclosporine and mycophenolate mofetil in a child with refractory Evans syndrome. Pediatr Rep. 2011;3(2):e15.

112. Rao VK, Dagan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005;129(4):534–538.

113. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2-3):119–125.

114. Earnshaw I, Thachil J. Example of the drug interaction between cyclosporin and orlistat, resulting in relapse of Evans’ syndrome. BMJ Case Rep. 2016;2016:bc2016217246.

115. Janić D, Krivokapić-Dokmanović L, Jovanović N, Lazić J, Rodić P, Janković S. Glucocorticoid-resistant Evans’ syndrome successfully controlled with low-dose cyclosporine. Int J Clin Pharmacol Ther. 2011;49(10):622–625.

116. Uçar B, Akgün N, Aydoğdu SD, Kirel B, İdem S. Treatment of refractory Evans’ syndrome with cyclosporine and prednisone. Pediatr Int. 1999;41(1):104–107.

117. Rackoff WR, Manno CS. Treatment of refractory Evans syndrome with alternate-day cyclosporine and prednisone. Am J Pediatr Hematol Oncol. 1994;16(2):156–159.

118. Emilia G, Mesiora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol. 1996;93(2):341–344.

119. Liu H, Shao Z, Jing L. The effectiveness of cyclosporin A in the treatment of autoimmune hemolytic anemia and Evans syndrome. Zhonghua Xue Ye Xue Za Zhi. 2001;22(11):581–583. Chinese.

120. Scardavoy A, Bussel J. Evans syndrome. Results of a pilot study utilizing a multigent treatment protocol. J Pediatr Hematol Oncol. 1995;17(4):290–295.

121. Duperti T, Felsher J, Brody F. Laparoscopic splenectomy for Evans syndrome. Surg Laparosc Endosc Percutan Tech. 2003;13(1):45–47.

122. Li Y, Pankaj P, Wang X, Wang Y, Peng B. Splenectomy in the management of Evans syndrome in adults: long-term follow up of 32 patients. Surg Pract. 2014;18(1):15–22.

123. Leone G, Pizzigallo E. Bacterial infections following splenectomy for malignant and nonmalignant hematologic diseases. Medit J Hematol Infect Dis. 2015;7(1):e2015057.

124. Price S, Shaw P, Kirk J, et al. Causes and consequences of splenectomy in ALPS-FAS. Blood. 2010;116(21):3908.

125. Bickenbach KA, Gonen M, Labow DM, et al. Indications for and efficacy of splenectomy for haematological disorders. Br J Surg. 2013;100(6):794–800.

126. Monga V, Malisie SM, Perepu U. Fatal pulmonary embolism following splenectomy in a patient with Evans’ syndrome: case report and review of the literature. Thromb J. 2017;15:18.

127. Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016;78(4):661–671.

128. Brodsky RA. High-dose chemotherapy in patients with severe autoimmune disease. Ann Intern Med. 1998;129:1031–1035.

129. Michallet AS, Rossignon J, Cazin B, Ysebaert L. Rituximab—cy clophosphamide—dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52(7):1401–1403.

130. Gombánsik N, Trahana M, Athanassiou M, Kanakoudi-Tsakalidou F. Evans syndrome: successful management with multi-agent treatment including intermediate-dose intravenous cyclophosphamide. J Pediatr Hematol Oncol. 1999;21(3):248–249.

131. Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2009;4(1):47–53.

132. Cheung WW, Wang Y, Tse E, Kwong YL. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica. 2006;91(5 Suppl):E13.

133. Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783–4785.

134. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114(4):891–898.

135. Gómez-Almaguer D, Colunga-Pedraza PR, Gómez-de León A, Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Jaime-Pérez JC. Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopenia. Br J Haematol. Epub 2017 December 21.

136. Ruiz-Arguelles GJ, Ruiz-Delgado GJ, Velázquez-Sánchez-de-Cima S, Zamora-Ortiz G. Simultaneous romiplostim, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab. Hematology. 2013;18(3):175–177.

137. González-Nieto JA, Martín-Suárez I, Quatrino S, et al. The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus. 2011;20(12):1321–1323.

138. Vaughan JE, Anwer F, Deeg HJ. Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? Vox Sang. 2016;110(1):5–11.

139. Raez E, Beatty PG, Adams RH. Treatment of severe Evans syndrome with an allogeneic cord blood transplant. Bone Marrow Transplant. 1997;20(5):427–429.

140. Oguma Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant. 2001;28(9):903–905.

141. Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003;101(1):71–77.

142. Urban C, Lackner H, Sovinz P, et al. Successful unrelated cord blood transplantation in a 7-year-old boy with Evans syndrome refractory to immunosuppression and double autologous stem cell transplantation. Eur J Haematol. 2006;76(6):526–530.
143. Passweg JR. Haematopoietic stem cell transplantation for immune thrombopenia and other refractory autoimmune cytopenias. *Best Pract Res Clin Haematol*. 2004;17(2):305–315.

144. Benesch M, Urban C, Platzbecker U, Passweg J. Stem cell transplantation for patients with Evans syndrome. *Expert Rev Clin Immunol*. 2009;5(3):341–348.

145. Au WY, Lo CM, Hawkins BR, Ma ES, Lie AK, Kwong YL. Evans’ syndrome complicating chronic graft versus host disease after cadaveric liver transplantation. *Transplantation*. 2001;72(3):527–528.

146. Page KM, Mendizabal AM, Prasad VK, et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. *Biol Blood Marrow Transplant*. 2008;14(10):1108–1117.

147. Kato I, Okada H, Nishida T, et al. Evans syndrome after autologous peripheral blood stem cell transplantation for recurrent Hodgkin lymphoma. *Pediatr Int*. 2016;58(9):933–936.

148. Keung VK, Cobos E, Bolanos-Meade J, Issarachai S, Brideau A, Morgan D. Evans syndrome after autologous bone marrow transplant for recurrent Hodgkin’s disease. *Bone Marrow Transplant*. 1997;20(12):1099–1101.

149. Kamezaki K, Fukuda T, Makino S, Harada M. Evans’ syndrome following autologous peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma. *Clin Exp Med*. 2004;26(4):291–293.

150. Chihara D, Sakamoto T, Arimoto-Miyamoto K, et al. Refractory Evans syndrome after autologous stem cell transplantation for multiple myeloma: management with a second transplantation. *Intern Med*. 2010;49(7):683–687.

151. Hwang-Bo S, Kim SK, Lee JW, et al. Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell transplantation in children. *Blood Res*. 2017;52(2):119–124.

152. Kheirouri S, Hadi V, Alizadeh M. Immunomodulatory effect of Nigella sativa oil on T lymphocytes in patients with rheumatoid arthritis. *Immunol Invest*. 2016;45(4):271–283.

153. Baghdadi H, Abdel-Aziz N, Ahmed NS, et al. Ameliorating role exerted by Al-Hijamah in autoimmune diseases: effect on serum autoantibodies and inflammatory mediators. *Int J Health Sci (Qassim)*. 2015;9(2):207–232.

154. El Sayed SM, Baghdadi H, Abou-Taleb A, et al. Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes. *J Blood Med*. 2014;5:219–237.

155. Teachey DT [database on the Internet]. Children’s Hospital of Philadelphia. Sirolimus for autoimmune disease of blood cells. Clin trials. Available from: https://clinicaltrials.gov/ct2/show/NCT00392951. NLM identifier: NCT00392951. Accessed May 21, 2018.

156. Bride KL, Vincent T, Smith-Whitley K, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. *Blood*. 2016;127(1):17–28.

157. Kashif M, Qureshi A, Adil SN, Khurshid M. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. *J Pak Med Assoc*. 2010;60(1):64–65.

158. Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. *Eur J Haematol*. 2005;75(1):60–64.

159. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. *Ann Intern Med*. 1998;129(12):1031–1035.